http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#Head http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#assertion http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#provenance http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#pubInfo http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#assertion http://purl.obolibrary.org/obo/MONDO_0005689 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0005689 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/DRUGBANK:DB14509 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association http://www.w3.org/2000/01/rdf-schema#label Currently, there are no FDA-approved pharmacotherapies available for CUD, though a number (eg, cannabinoids, antidepressants, anxiolytics, and glutamatergic modulators) have been proposed for off-label use. We identified 12 trials examining psychopharmacological interventions for the treatment of cannabis use disorder. Trials examined antidepressants (ie, escitalopram, fluoxetine, bupropion, nefazodone, venlafaxine, vilazodone), antipsychotics (ie, clozapine, ziprasidone), buspirone, mood stabilizers (ie, divalproex, lithium), and atomoxetine. Overall, studies found that antidepressants as a class were less effective than placebo for the achievement of abstinence (moderate SOE). There was no difference between antidepressants (moderate SOE) or buspirone (low SOE) and placebo in reducing overall cannabis use or retention in treatment. We found low strength evidence of no difference from placebo for antidepressants or buspirone on harms. Antidepressant medications did not impact secondary outcomes (low SOE). Findings for all other psychopharmacotherapies and drug/outcome combinations were either insufficient or were not identified in the current literature. http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#context http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/32227801 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#context http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#context http://www.w3.org/2000/01/rdf-schema#label Adults https://identifiers.org/DRUGBANK:DB14509 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#provenance http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#assertion http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T19:10:14.728806 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#pubInfo http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#sig http://purl.org/nanopub/x/hasSignature d09zgNbAV+KIQm4hZWSQAxL3NaTFYxvDzG/FXpPJPOyr2FtgMXd6k/tf1m3YtCUHrSoeMcH+pSGRKV2F6zk0CK0pQamjagx3rsSLAOOTVreHXpPm9+orWqN2MVEhVeHl4lB5UwWQuLY2qjXhIxrorhwwUly4iSR7XRJGg4kBe5k= http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.w3.org/ns/prov#generatedAtTime 2021-08-24T19:10:14.728806 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAYc3-eniB62UmDMyHdOjPp2PKhFMRq03wu7Xcj2uiObk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY